{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:17:31Z","timestamp":1760710651600,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Medication-related osteonecrosis of the jaw (MRONJ) is a severe and difficult-to-treat adverse event of bone-modifying agents. Therefore predictive strategies determining patients at risk for a prolonged healing duration are needed to optimize treatment. Thus, the present study evaluates whether or not bone turnover markers can be used to predict the healing duration in MRONJ patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>The present study is a retrospective data analysis of patients suffering from MRONJ and positive histology for <jats:italic>Actinomyces<\/jats:italic> spp., who were identified at the General Hospital Vienna from 2014 to 2018. During the first visit, the patients\u2019 demographics and levels of bone formation parameters were compiled. Healing times were analysed by Cox regression in dependence on these factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 52 patients were identified who fulfilled the inclusion criteria. The indication for bone-modifying agents was breast cancer (n\u2009=\u200921), prostate cancer (n\u2009=\u200914), multiple myeloma (n\u2009=\u20096) and other malignant diseases (n\u2009=\u200911). In 43 (82.7%) of our patients, we were able to document complete mucosal healing. Furthermore, patients who responded faster to therapy showed higher levels of C-telopeptide (P\u2009&lt;\u20090.05), osteocalcin (P\u2009&lt;\u20090.05) and bone-specific alkaline phosphatase (P\u2009&lt;\u20090.05), but lower levels of 1.25-dihydroxyvitamin D (P\u2009&lt;\u20090.05) than slower responding patients. No correlation was found regarding parathyroid hormone or calcitonin levels. Interestingly, patients who had a slower response were less likely to report dental procedures, but more likely to report a history of chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>CTX and osteocalcin levels may be used for predicting healing duration for MRONJ.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-021-06361-z","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T01:03:01Z","timestamp":1625014981000},"page":"7895-7902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bone turnover markers can predict healing time in medication-related osteonecrosis of the jaw"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9181-8614","authenticated-orcid":false,"given":"Lorenz","family":"Schubert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenter","family":"Russmueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heimo","family":"Lagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Tobudic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Heindel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kundi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3500-7205","authenticated-orcid":false,"given":"Christoph","family":"Steininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"6361_CR1","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/ncponc0320","volume":"2","author":"MJ Seibel","year":"2005","unstructured":"Seibel MJ (2005) Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2:504\u20135017. https:\/\/doi.org\/10.1038\/ncponc0320","journal-title":"Nat Clin Pract Oncol"},{"key":"6361_CR2","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J et al (2014) American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg 72:1938\u20131956. https:\/\/doi.org\/10.1016\/j.joms.2014.04.031","journal-title":"J Oral Maxillofac Surg"},{"key":"6361_CR3","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ijom.2015.01.026","volume":"44","author":"R Fliefel","year":"2015","unstructured":"Fliefel R, Tr\u00f6ltzsch M, K\u00fchnisch J et al (2015) Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 44:568\u2013585. https:\/\/doi.org\/10.1016\/j.ijom.2015.01.026","journal-title":"Int J Oral Maxillofac Surg"},{"key":"6361_CR4","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","volume":"15","author":"T Mashiba","year":"2010","unstructured":"Mashiba T, Hirano T, Turner CH et al (2010) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in Dog Rib. J Bone Miner Res 15:613\u2013620. https:\/\/doi.org\/10.1359\/jbmr.2000.15.4.613","journal-title":"J Bone Miner Res"},{"key":"6361_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","volume":"19","author":"WX Qi","year":"2014","unstructured":"Qi WX, Tang LN, He AN et al (2014) Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol 19:403\u2013410. https:\/\/doi.org\/10.1007\/s10147-013-0561-6","journal-title":"Int J Clin Oncol"},{"key":"6361_CR6","doi-asserted-by":"publisher","first-page":"31604","DOI":"10.1038\/srep31604","volume":"6","author":"G Russmueller","year":"2016","unstructured":"Russmueller G, Seemann R, Weiss K et al (2016) The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. Sci Rep 6:31604. https:\/\/doi.org\/10.1038\/srep31604","journal-title":"Sci Rep"},{"key":"6361_CR7","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1128\/iai.64.7.2371-2380.1996","volume":"64","author":"SP Nair","year":"1996","unstructured":"Nair SP, Meghji S, Wilson M et al (1996) Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun 64:2371\u20132380","journal-title":"Infect Immun"},{"key":"6361_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","volume":"67","author":"MR Allen","year":"2009","unstructured":"Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67:61\u201370. https:\/\/doi.org\/10.1016\/j.joms.2009.01.007","journal-title":"J Oral Maxillofac Surg"},{"key":"6361_CR9","doi-asserted-by":"publisher","unstructured":"Hayes DF, Markus HS, Leslie RD, Topol EJ (2014) Personalized medicine: risk prediction, targeted therapies and mobile health technology. BMC Med 12: https:\/\/doi.org\/10.1186\/1741-7015-12-37","DOI":"10.1186\/1741-7015-12-37"},{"key":"6361_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bone.2013.08.005","volume":"57","author":"JW Kim","year":"2013","unstructured":"Kim JW, Kong KA, Kim SJ et al (2013) Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates. Bone 57:201\u2013205. https:\/\/doi.org\/10.1016\/j.bone.2013.08.005","journal-title":"Bone"},{"key":"6361_CR11","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1016\/j.joms.2009.04.067","volume":"67","author":"YD Kwon","year":"2009","unstructured":"Kwon YD, Kim DY, Ohe JY et al (2009) Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 67:2644\u20132648. https:\/\/doi.org\/10.1016\/j.joms.2009.04.067","journal-title":"J Oral Maxillofac Surg"},{"key":"6361_CR12","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","volume":"67","author":"R Kunchur","year":"2009","unstructured":"Kunchur R, Need A, Hughes T, Goss A (2009) Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 67:1167\u20131173. https:\/\/doi.org\/10.1016\/j.joms.2009.02.004","journal-title":"J Oral Maxillofac Surg"},{"key":"6361_CR13","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.joms.2010.05.043","volume":"68","author":"TS Lazarovici","year":"2010","unstructured":"Lazarovici TS, Mesilaty-Gross S, Vered I et al (2010) Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg 68:2241\u20132247. https:\/\/doi.org\/10.1016\/j.joms.2010.05.043","journal-title":"J Oral Maxillofac Surg"},{"key":"6361_CR14","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.oraloncology.2008.01.012","volume":"44","author":"JV Bagan","year":"2008","unstructured":"Bagan JV, Jim\u00e9nez Y, G\u00f3mez D et al (2008) Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol 44:1088\u20131089. https:\/\/doi.org\/10.1016\/j.oraloncology.2008.01.012","journal-title":"Oral Oncol"},{"key":"6361_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.tripleo.2008.01.033","volume":"106","author":"S Lehrer","year":"2008","unstructured":"Lehrer S, Montazem A, Ramanathan L et al (2008) Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology 106:389\u2013391. https:\/\/doi.org\/10.1016\/j.tripleo.2008.01.033","journal-title":"Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology"},{"key":"6361_CR16","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","volume":"65","author":"RE Marx","year":"2007","unstructured":"Marx RE, Cillo JE, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of Risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397\u20132410. https:\/\/doi.org\/10.1016\/j.joms.2007.08.003","journal-title":"J Oral Maxillofac Surg"},{"key":"6361_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s13167-019-0160-3","volume":"10","author":"M Salgueiro","year":"2019","unstructured":"Salgueiro M, Stribos M, Zhang LF et al (2019) Value of pre-operative CTX serum levels in the prediction of medication-related osteonecrosis of the jaw (MRONJ): a retrospective clinical study. EPMA J 10:21\u201329. https:\/\/doi.org\/10.1007\/s13167-019-0160-3","journal-title":"EPMA J"},{"key":"6361_CR18","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1002\/jbmr.3191","volume":"32","author":"S Hayashida","year":"2017","unstructured":"Hayashida S, Soutome S, Yanamoto S et al (2017) Evaluation of the treatment strategies for medication-related osteonecrosis of the jaws (MRONJ) and the factors affecting treatment outcome: a multicenter retrospective study with propensity score matching analysis. J Bone Miner Res 32:2022\u20132029. https:\/\/doi.org\/10.1002\/jbmr.3191","journal-title":"J Bone Miner Res"},{"key":"6361_CR19","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/hed.20864","volume":"30","author":"A Wutzl","year":"2008","unstructured":"Wutzl A, Biedermann E, Wanschitz F et al (2008) Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 30:1224\u20131230. https:\/\/doi.org\/10.1002\/hed.20864","journal-title":"Head Neck"},{"key":"6361_CR20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.oraloncology.2012.07.008","volume":"49","author":"D Holzinger","year":"2013","unstructured":"Holzinger D, Seemann R, Klug C et al (2013) Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs). Oral Oncol 49:66\u201370. https:\/\/doi.org\/10.1016\/j.oraloncology.2012.07.008","journal-title":"Oral Oncol"},{"key":"6361_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/jac\/dkv347","volume":"71","author":"C Steininger","year":"2016","unstructured":"Steininger C, Willinger B (2016) Resistance patterns in clinical isolates of pathogenic Actinomyces species. J Antimicrob Chemother 71:422\u2013427. https:\/\/doi.org\/10.1093\/jac\/dkv347","journal-title":"J Antimicrob Chemother"},{"key":"6361_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/IDR.S39601","volume":"7","author":"F Valour","year":"2014","unstructured":"Valour F, S\u00e9n\u00e9chal A, Dupieux C et al (2014) Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect Drug Resist 7:183\u2013197. https:\/\/doi.org\/10.2147\/IDR.S39601","journal-title":"Infect Drug Resist"},{"key":"6361_CR23","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.joms.2014.02.036","volume":"72","author":"A Hutcheson","year":"2014","unstructured":"Hutcheson A, Cheng A, Kunchar R et al (2014) A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study. J Oral Maxillofac Surg 72:1456\u20131462. https:\/\/doi.org\/10.1016\/j.joms.2014.02.036","journal-title":"J Oral Maxillofac Surg"},{"key":"6361_CR24","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.jcms.2017.09.015","volume":"45","author":"N Heim","year":"2017","unstructured":"Heim N, Warwas FB, Wilms CT et al (2017) Vitamin D (25-OHD) deficiency may increase the prevalence of medication-related osteonecrosis of the jaw. J Cranio-Maxillofacial Surg 45:2068\u20132074. https:\/\/doi.org\/10.1016\/j.jcms.2017.09.015","journal-title":"J Cranio-Maxillofacial Surg"},{"key":"6361_CR25","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1002\/jbmr.23","volume":"25","author":"A Hokugo","year":"2010","unstructured":"Hokugo A, Christensen R, Chung EM et al (2010) Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 25:1337\u20131349. https:\/\/doi.org\/10.1002\/jbmr.23","journal-title":"J Bone Miner Res"},{"key":"6361_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/hed.21708","volume":"34","author":"A Wutzl","year":"2012","unstructured":"Wutzl A, Pohl S, Sulzbacher I et al (2012) Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws. Head Neck 34:194\u2013200. https:\/\/doi.org\/10.1002\/hed.21708","journal-title":"Head Neck"},{"key":"6361_CR27","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1200\/JCO.19.02192","volume":"38","author":"IW Sim","year":"2020","unstructured":"Sim IW, Borromeo GL, Tsao C et al (2020) Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: a placebo-controlled, randomized trial. J Clin Oncol 38:2971\u20132980. https:\/\/doi.org\/10.1200\/JCO.19.02192","journal-title":"J Clin Oncol"},{"key":"6361_CR28","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1002\/jbmr.1800","volume":"27","author":"C Capriani","year":"2012","unstructured":"Capriani C, Irani D, Bilezikian JP (2012) Safety of osteoanabolic therapy: a decade of experience. J Bone Miner Res 27:2419\u20132428. https:\/\/doi.org\/10.1002\/jbmr.1800","journal-title":"J Bone Miner Res"},{"key":"6361_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.oooo.2016.06.019","volume":"122","author":"AA Owosho","year":"2016","unstructured":"Owosho AA, Estilo CL, Huryn JM, Yom SHK (2016) Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol 122:455\u2013459. https:\/\/doi.org\/10.1016\/j.oooo.2016.06.019","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"6361_CR30","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.joms.2012.04.001","volume":"70","author":"JJ Freiberger","year":"2012","unstructured":"Freiberger JJ, Padilla-Burgos R, McGraw T et al (2012) What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg 70:1573\u20131583. https:\/\/doi.org\/10.1016\/j.joms.2012.04.001","journal-title":"J Oral Maxillofac Surg"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06361-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06361-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06361-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T12:37:25Z","timestamp":1635251845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06361-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6361"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06361-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"17 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of the Medical University of Vienna, Austria (ECS 2055\/2016), and all study-related procedures were conducted according to the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable due to retrospective study design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable due to retrospective study design.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}